Jonathan Cheng, MD, PhD, serves as Medical Director
4.0 out of 5 from our editorial team, reflecting strong pricing fundamentals and transparent pharmacy sourcing weighed against the complete absence of independent patient reviews
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes
"Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data"
It is expected to be commercially available in pharmacies in the second quarter of 2026
For example, eloralintide studies NCT07321886, NCT07392190, NCT07215559, and related ENLIGHTEN studies